It is with deep sadness that we announce our dear friend and colleague Torsten Goesch passed away unexpectedly earlier this week. Torsten was a highly respected member of the Rosetta team and he is much missed. Our thoughts and condolences go out to Torsten's family during this difficult time.
Biotech
Novagali Pharma specialised in developing ocular therapeutics for different segments of the eye (surface, anterior and posterior segments). Their formulations were based on proprietary technology platforms Novasorb® and Eyeject®, which optimized bioavailability of drugs as well as safety and comfort for the patient. Novagali Pharma was acquired by Santen for $139 million in 2011.
Location
Évry-Courcouronnes, France
History
Acquired by Santen Pharma for $139 million in 2011
Registered in England No. 3941653 | VAT No. GB 765 3567 96
© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority
